Resources
Explore how healthcare organizations, researchers, and life sciences partners from our global community use TriNetX to turn real-world patient data into evidence that drives progress.
Discover an insightful webinar that focuses on the transformative potential of real-world data (RWD) in clinical research and healthcare strategy.
Pharmacoepidemiology, the study of the use and effects of drugs in large populations, has seen a significant evolution with the increasing availability of real-world data (RWD)
Join us for an insightful webinar, during which TriNetX experts explore how Europe’s evolving healthcare landscape is redefining the role of real-world evidence (RWE).
The global use of angiotensin receptor neprilysin inhibitor (ARNI) in clinical practice, especially in patients with heart failure and below-normal ejection fraction (HFbnEF), has not been thoroughly evaluated.
his study aimed to assess recent trends in the US use of glucagon-like peptide-1 receptor agonist (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitor (SGLT2i) in people with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), including incident use following newly diagnosed ASCVD.
Clinical research networks facilitate collaborative research, but data sharing remains a common barrier.
Finally, we outline typical use cases for the RWE-DE where it can broaden the reach of the types of questions that can be addressed by the Sentinel system.
n this cohort study of 1854 patients, the hazard ratio for mortality (0.95) was incongruous with that of the benchmark trial (0.49).
The landscape of clinical trials is evolving, and with it, the approach to site selection. A more patient-centric model is emerging, which flips the traditional process on its head.
Join industry-leading experts as they delve into the latest real-world data (RWD) and real-world evidence (RWE) use cases, highlighting groundbreaking research and publications.
Company recognized with high-level certification for abiding by Spain’s strongest data security measures, sets a new standard for healthcare data protection within its TriNetX LIVE™ platform.
While artificial intelligence (AI) brings significant advancements to clinical trials—including patient recruitment, data analysis, and real-time monitoring—it is not a panacea for the complexities of clinical development.
Upcoming Webinar
From Data to Evidence: A Framework for RWD Study Design & Causal Inference
Thursday, July 16 | 11am ET
Generating credible evidence from real-world data (RWD) requires more than access to data — it demands intentional alignment between the research question, study design, and data source. Yet even experienced teams fall into the trap of starting with the data and working backward, a shortcut that can undermine the trustworthiness of study findings.
Join TriNetX Chief Scientific Officer Jeffrey Brown, PhD, and Miguel Hernán, MD, PhD, ScD, Director of CAUSALab at Harvard, as they walk through a practical framework for designing rigorous RWD studies for causal inference. Attendees will leave with concrete tools for sequencing their research approach, evaluating data fitness, and applying sound decision-making to their own studies.
Join a global community of innovators. Discover how to turn real-world data into groundbreaking clinical insights.
Meet TriNetX at Events
Bridge the gap between raw data and patient care. Meet the team at flagship healthcare conferences across the globe, and learn how to leverage the TriNetX ecosystem to streamline trial timelines, improve site collaboration, and publish research that changes lives.
